133 related articles for article (PubMed ID: 35364257)
21. Superparamagnetic iron oxide nanoparticles modified with polyethylenimine and galactose for siRNA targeted delivery in hepatocellular carcinoma therapy.
Yang Z; Duan J; Wang J; Liu Q; Shang R; Yang X; Lu P; Xia C; Wang L; Dou K
Int J Nanomedicine; 2018; 13():1851-1865. PubMed ID: 29618926
[TBL] [Abstract][Full Text] [Related]
22. Galactosylated polyaspartamide copolymers for siRNA targeted delivery to hepatocellular carcinoma cells.
Cavallaro G; Farra R; Craparo EF; Sardo C; Porsio B; Giammona G; Perrone F; Grassi M; Pozzato G; Grassi G; Dapas B
Int J Pharm; 2017 Jun; 525(2):397-406. PubMed ID: 28119125
[TBL] [Abstract][Full Text] [Related]
23. Sustained and targeted delivery of siRNA/DP7-C nanoparticles from injectable thermosensitive hydrogel for hepatocellular carcinoma therapy.
Zhao B; Zhou B; Shi K; Zhang R; Dong C; Xie D; Tang L; Tian Y; Qian Z; Yang L
Cancer Sci; 2021 Jun; 112(6):2481-2492. PubMed ID: 33792132
[TBL] [Abstract][Full Text] [Related]
24. Targeted delivery of siRNAs against hepatocellular carcinoma-related genes by a galactosylated polyaspartamide copolymer.
Perrone F; Craparo EF; Cemazar M; Kamensek U; Drago SE; Dapas B; Scaggiante B; Zanconati F; Bonazza D; Grassi M; Truong N; Pozzato G; Farra R; Cavallaro G; Grassi G
J Control Release; 2021 Feb; 330():1132-1151. PubMed ID: 33212117
[TBL] [Abstract][Full Text] [Related]
25. Aggregation-Induced Emission (AIE) and Magnetic Resonance Imaging Characteristics for Targeted and Image-Guided siRNA Therapy of Hepatocellular Carcinoma.
Hou YC; Zhang C; Zhang ZJ; Xia L; Rao KQ; Gu LH; Wu YC; Lv ZC; Wu HX; Zuo XL; Li F; Feng H; Xia Q
Adv Healthc Mater; 2022 Sep; 11(17):e2200579. PubMed ID: 35749736
[TBL] [Abstract][Full Text] [Related]
26. RecQL1 DNA repair helicase: A potential tumor marker and therapeutic target against hepatocellular carcinoma.
Futami K; Ogasawara S; Goto H; Yano H; Furuichi Y
Int J Mol Med; 2010 Apr; 25(4):537-45. PubMed ID: 20198302
[TBL] [Abstract][Full Text] [Related]
27. Theranostical nanosystem-mediated identification of an oncogene and highly effective therapy in hepatocellular carcinoma.
Guo Y; Wang J; Zhang L; Shen S; Guo R; Yang Y; Chen W; Wang Y; Chen G; Shuai X
Hepatology; 2016 Apr; 63(4):1240-55. PubMed ID: 26680504
[TBL] [Abstract][Full Text] [Related]
28. Fucoidan-induced ID-1 suppression inhibits the in vitro and in vivo invasion of hepatocellular carcinoma cells.
Cho Y; Cho EJ; Lee JH; Yu SJ; Kim YJ; Kim CY; Yoon JH
Biomed Pharmacother; 2016 Oct; 83():607-616. PubMed ID: 27459117
[TBL] [Abstract][Full Text] [Related]
29. Effects of short interfering RNA-mediated gene silencing of SKA1 on proliferation of hepatocellular carcinoma cells.
Qin X; Yuan B; Xu X; Huang H; Liu Y
Scand J Gastroenterol; 2013 Nov; 48(11):1324-32. PubMed ID: 24010405
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of human hepatocellular carcinoma tumor angiogenesis by siRNA silencing of VEGF via hepatic artery perfusion.
Zou Y; Guo CG; Zhang MM
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(24):4751-61. PubMed ID: 26744866
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma.
Farra R; Grassi M; Grassi G; Dapas B
World J Gastroenterol; 2015 Aug; 21(30):8994-9001. PubMed ID: 26290628
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of connective tissue growth factor overexpression decreases growth of hepatocellular carcinoma cells in vitro and in vivo.
Jia XQ; Cheng HQ; Li H; Zhu Y; Li YH; Feng ZQ; Zhang JP
Chin Med J (Engl); 2011 Nov; 124(22):3794-9. PubMed ID: 22340243
[TBL] [Abstract][Full Text] [Related]
33. Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.
Liang X; Wang Y; Shi H; Dong M; Han H; Li Q
Int J Nanomedicine; 2021; 16():2569-2584. PubMed ID: 33833512
[TBL] [Abstract][Full Text] [Related]
34. EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex.
Subramanian N; Kanwar JR; Athalya PK; Janakiraman N; Khetan V; Kanwar RK; Eluchuri S; Krishnakumar S
J Biomed Sci; 2015 Jan; 22():4. PubMed ID: 25576037
[TBL] [Abstract][Full Text] [Related]
35. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma.
Huang KW; Lai YT; Chern GJ; Huang SF; Tsai CL; Sung YC; Chiang CC; Hwang PB; Ho TL; Huang RL; Shiue TY; Chen Y; Wang SK
Biomacromolecules; 2018 Jun; 19(6):2330-2339. PubMed ID: 29808997
[TBL] [Abstract][Full Text] [Related]
36. FMRP regulates STAT3 mRNA localization to cellular protrusions and local translation to promote hepatocellular carcinoma metastasis.
Shen Z; Liu B; Wu B; Zhou H; Wang X; Cao J; Jiang M; Zhou Y; Guo F; Xue C; Wu ZS
Commun Biol; 2021 May; 4(1):540. PubMed ID: 33972660
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of B7-H4 suppresses tumor progression of hepatocellular carcinoma.
Dong L; Xie L; Li M; Dai H; Wang X; Wang P; Zhang Q; Liu W; Hu X; Zhao M
Sci Rep; 2019 Oct; 9(1):14854. PubMed ID: 31619714
[TBL] [Abstract][Full Text] [Related]
38. Targeted nanobubbles in low-frequency ultrasound-mediated gene transfection and growth inhibition of hepatocellular carcinoma cells.
Wu B; Qiao Q; Han X; Jing H; Zhang H; Liang H; Cheng W
Tumour Biol; 2016 Sep; 37(9):12113-12121. PubMed ID: 27216880
[TBL] [Abstract][Full Text] [Related]
39. Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy.
Han L; Tang C; Yin C
Biomaterials; 2014 May; 35(15):4589-600. PubMed ID: 24613049
[TBL] [Abstract][Full Text] [Related]
40. Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappaB-inducing kinase-specific siRNA using liver-targeting liposomes.
Cho HA; Park IS; Kim TW; Oh YK; Yang KS; Kim JS
Arch Pharm Res; 2009 Jul; 32(7):1077-86. PubMed ID: 19641890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
